Sonneveld P, Kurth K H, Hagemeyer A, Abels J
Department of Hematology, University Hospital Rotterdam, Dijkzigt, The Netherlands.
Cancer. 1990 Jan 1;65(1):23-5. doi: 10.1002/1097-0142(19900101)65:1<23::aid-cncr2820650107>3.0.co;2-q.
Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C. In one patient, karyotypic abnormalities (-5, 7q-) typical of a therapy induced malignancy were associated with rapid progression of a refractory anemia with excess blasts in transformation to an acute non-lymphocytic leukemia. Intravesical chemotherapy may be associated with a risk of secondary malignancy.
报告了两例浅表性膀胱癌患者在接受膀胱内注射依托格鲁、阿霉素和丝裂霉素C化疗数年之后发生血液系统恶性肿瘤的病例。其中一名患者出现了典型的治疗引起的恶性肿瘤的核型异常（-5，7q-），同时伴有难治性贫血伴原始细胞增多快速进展为急性非淋巴细胞白血病。膀胱内化疗可能与继发恶性肿瘤风险相关。
